Eliciting patients’ preferences for outpatient treatment of febrile neutropenia: a discrete choice experiment

[1] Kuderer NM(2006)Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients Cancer 106 2258-2266

[2] Dale DC(2010)Evaluation of direct medical costs of hospitalization for febrile neutropenia Cancer 116 742-748

[3] Crawford J(2006)The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies Haematologica 91 215-222

[4] Lathia N(2008)Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice Support Care Cancer 16 485-491

[5] Mittmann N(2003)Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study Br J Cancer 89 43-49

[6] DeAngelis C(2006)Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications J Clin Oncol 24 4129-4134

[7] Cherif H(2007)The outpatient management of low-risk febrile patients with neutropenia: risk assessment over the telephone Support Care Cancer 15 287-291

[8] Johansson E(2006)Once daily, oral, outpatient quinolone monotherapy for low-risk cancer patients with fever and neutropenia: a pilot study of 40 patients based on validated risk-prediction rules Cancer 106 2489-2494

[9] Bjorkholm M(2007)Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients Oncologist 12 478-483

[10] Kalin M(2008)Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia J Clin Oncol 26 606-611

[1] Kuderer NM(2006)Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients Cancer 106 2258-2266

[2] Dale DC(2010)Evaluation of direct medical costs of hospitalization for febrile neutropenia Cancer 116 742-748

[3] Crawford J(2006)The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies Haematologica 91 215-222

[4] Lathia N(2008)Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice Support Care Cancer 16 485-491

[5] Mittmann N(2003)Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study Br J Cancer 89 43-49

[6] DeAngelis C(2006)Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications J Clin Oncol 24 4129-4134

[7] Cherif H(2007)The outpatient management of low-risk febrile patients with neutropenia: risk assessment over the telephone Support Care Cancer 15 287-291

[8] Johansson E(2006)Once daily, oral, outpatient quinolone monotherapy for low-risk cancer patients with fever and neutropenia: a pilot study of 40 patients based on validated risk-prediction rules Cancer 106 2489-2494

[9] Bjorkholm M(2007)Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients Oncologist 12 478-483

[10] Kalin M(2008)Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia J Clin Oncol 26 606-611